“Osteosarcoma remains a therapeutic challenge due to its aggressive behavior and high metastatic potential, necessitating exploration of novel treatment modalities”, states the study’s abstract. “Cannabidiol (CBD), a non-psychoactive phytocannabinoid with emerging anticancer properties, has shown promise in preclinical cancer models. However, its mechanisms of action in osteosarcoma remain incompletely understood.”
With that in mind, “This study systematically investigates the antitumor effects of CBD on osteosarcoma and elucidates its molecular targets within the TNF-α/NF-κB/CCL5 signaling axis.”
Conducted by researchers at Shandong University and Harbin Medical University, researchers used cell-based assays and a mouse model, finding that CBD suppressed osteosarcoma cell proliferation, migration, and invasion, while also reducing tumor growth in vivo.
The team identified that CBD binds directly to the NF-κB subunit p65, blocking its ability to activate transcription of the chemokine CCL5. This disruption also interfered with a previously unrecognized positive feedback loop between p65 and CCL5, which helps sustain inflammatory signaling in osteosarcoma cells. By targeting this loop, CBD not only inhibited tumor-promoting inflammation but also weakened the cancer’s ability to proliferate and spread.
The researchers used a combination of molecular docking, protein-binding assays, and gene expression analysis to confirm CBD’s direct interaction with the p65 protein and its downstream effects.
Hellbound and Down 